Neoadjuvant Therapy for Non‐Small Cell Lung Cancer: Recent Advances and Future Directions
6 affiliations
- 1School of Clinical Medicine, Shandong Second Medical University, Weifang, China, Shandong Cancer Hospital and Institute, Affiliated Hospital of Weifang Medical University, School of Clinical Medicine, Weifang Medical University, Weifang, Shandong, China.
- 2Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- 3Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
- 4Shandong First Medical University, Jinan, Shandong, China.
- 5Weifang Medical University, Weifang, Shandong, China.
- 6Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Abstract
Neoadjuvant therapy has become an integral component of the multidisciplinary management of resectable non–small cell lung cancer (NSCLC). The introduction of immune checkpoint inhibitors (ICIs) has transformed the perioperative treatment landscape by improving pathological response rates, reducing the risk of recurrence, and offering the potential for durable survival benefits. In recent years, multiple neoadjuvant strategies, including ICI monotherapy, chemoimmunotherapy, dual immune checkpoint blockade, and combinations with radiotherapy, anti‐angiogenic agents, or targeted therapies, have been actively investigated to further optimize treatment efficacy. Immune checkpoint inhibitors (ICIs) are reshaping neoadjuvant strategies for resectable NSCLC. LCMC3 confirmed the feasibility of ICIs monotherapy, while CheckMate 816 and NADIM demonstrated that ICI–chemotherapy combinations markedly improve major pathological response and survival outcomes. Emerging perioperative studies, including CheckMate 77 T and AEGEAN, further support the integration of immunotherapy into standard treatment paradigms. Radiotherapy enhances tumor immunogenicity and shows synergy with ICIs, as highlighted in PACIFIC and KEYNOTE‐799. Although clinical evidence for ICI–anti‐angiogenic combinations remains preliminary, their mechanistic rationale is strong. In EGFR‐ or ALK‐altered NSCLC, emerging data suggest that neoadjuvant targeted therapy and carefully selected immunotherapy‐based strategies may further improve disease control while delaying recurrence. Despite these advances, several challenges remain, including the paucity of long‐term survival data, discordance between pathological responses and clinical benefit, treatment‐related toxicities, optimal treatment sequencing, biomarker‐guided patient selection, and mechanisms of primary or acquired resistance. Advances in predictive modeling based on PD‐L1 expression, tumor mutational burden (TMB), radiomics, nomograms, circulating tumor DNA, and multi‐omics biomarkers, together with a deeper understanding of metabolic–immune crosstalk, are expected to facilitate precision perioperative immunotherapy. This review comprehensively summarizes current evidence regarding neoadjuvant immunotherapy strategies for resectable NSCLC, highlights pivotal clinical trial findings, discusses emerging combination approaches and predictive biomarkers, and outlines future research directions aimed at improving personalized treatment and long‐term patient outcomes.
Related
- Neoadjuvant systemic therapy and the evolution of axillary management in breast cancer: a mini review and future directions
- Advances in predictive factors for pathological complete response after neoadjuvant therapy in locally advanced rectal cancer
- Reaching for the Exposome: Recent Advances and Future Directions for Understanding Environment-Brain-Cognition Links.
- Antibody Discovery and Therapeutics in Spondyloarthritis: Recent Advances and Future Directions.
- Emerging Therapeutic Strategies for Neurodegenerative Diseases: A Comprehensive Review of Recent Advances and Future Directions
BibTeX
@article{an2026neoadjuvant,
title = {{Neoadjuvant Therapy for Non‐Small Cell Lung Cancer: Recent Advances and Future Directions}},
author = {Hao An and Junfeng Zhao and Wenjie Chen and Ying Li and Yifei Yan and Chen Zhou and Ruyue Li and Xiujing Yao and Xue Dong and Xingying Yang and Yongjuan Hu and Jiaxuan Chen and Chuankun Han and Yingrui Bai and Yali Xu and Yintao Li},
journal = {Cancer medicine},
year = {2026},
month = oct,
doi = {10.1002/cam4.72350},
url = {https://europepmc.org/article/PMC/PMC13717951},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Neoadjuvant Therapy for Non‐Small Cell Lung Cancer: Recent Advances and Future Directions
AU - Hao An
AU - Junfeng Zhao
AU - Wenjie Chen
AU - Ying Li
AU - Yifei Yan
AU - Chen Zhou
AU - Ruyue Li
AU - Xiujing Yao
AU - Xue Dong
AU - Xingying Yang
AU - Yongjuan Hu
AU - Jiaxuan Chen
AU - Chuankun Han
AU - Yingrui Bai
AU - Yali Xu
AU - Yintao Li
PY - 2026
DA - 2026/10/29
JO - Cancer medicine
DO - 10.1002/cam4.72350
UR - https://europepmc.org/article/PMC/PMC13717951
AB - Neoadjuvant therapy has become an integral component of the multidisciplinary management of resectable non–small cell lung cancer (NSCLC). The introduction of immune checkpoint inhibitors (ICIs) has transformed the perioperative treatment landscape by improving pathological response rates, reducing the risk of recurrence, and offering the potential for durable survival benefits. In recent years, multiple neoadjuvant strategies, including ICI monotherapy, chemoimmunotherapy, dual immune checkpoint blockade, and combinations with radiotherapy, anti‐angiogenic agents, or targeted therapies, have been actively investigated to further optimize treatment efficacy. Immune checkpoint inhibitors (ICIs) are reshaping neoadjuvant strategies for resectable NSCLC. LCMC3 confirmed the feasibility of ICIs monotherapy, while CheckMate 816 and NADIM demonstrated that ICI–chemotherapy combinations markedly improve major pathological response and survival outcomes. Emerging perioperative studies, including CheckMate 77 T and AEGEAN, further support the integration of immunotherapy into standard treatment paradigms. Radiotherapy enhances tumor immunogenicity and shows synergy with ICIs, as highlighted in PACIFIC and KEYNOTE‐799. Although clinical evidence for ICI–anti‐angiogenic combinations remains preliminary, their mechanistic rationale is strong. In EGFR‐ or ALK‐altered NSCLC, emerging data suggest that neoadjuvant targeted therapy and carefully selected immunotherapy‐based strategies may further improve disease control while delaying recurrence. Despite these advances, several challenges remain, including the paucity of long‐term survival data, discordance between pathological responses and clinical benefit, treatment‐related toxicities, optimal treatment sequencing, biomarker‐guided patient selection, and mechanisms of primary or acquired resistance. Advances in predictive modeling based on PD‐L1 expression, tumor mutational burden (TMB), radiomics, nomograms, circulating tumor DNA, and multi‐omics biomarkers, together with a deeper understanding of metabolic–immune crosstalk, are expected to facilitate precision perioperative immunotherapy. This review comprehensively summarizes current evidence regarding neoadjuvant immunotherapy strategies for resectable NSCLC, highlights pivotal clinical trial findings, discusses emerging combination approaches and predictive biomarkers, and outlines future research directions aimed at improving personalized treatment and long‐term patient outcomes.
SN - 2045-7634
ER -